1. Home
  2. RERE vs WVE Comparison

RERE vs WVE Comparison

Compare RERE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATRenew Inc.

RERE

ATRenew Inc.

SELL

Current Price

$3.93

Market Cap

832.8M

ML Signal

SELL

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$3.14

Market Cap

744.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RERE
WVE
Founded
2011
2012
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
832.8M
744.8M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
RERE
WVE
Price
$3.93
$3.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
19
Target Price
$6.62
★ $18.06
AVG Volume (30 Days)
472.8K
★ 2.9M
Earning Date
11-19-2026
11-09-2026
Dividend Yield
★ 2.68%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $3,704,000.00
Revenue This Year
$27.40
$19.21
Revenue Next Year
$21.96
N/A
P/E Ratio
$34.57
★ N/A
Revenue Growth
N/A
★ 149.43
52 Week Low
$3.50
$3.27
52 Week High
$6.47
$21.73

Technical Indicators

Market Signals
Indicator
RERE
WVE
Relative Strength Index (RSI) 52.57 20.10
Support Level $3.81 N/A
Resistance Level $4.10 $6.33
Average True Range (ATR) 0.10 0.19
MACD 0.02 -0.02
Stochastic Oscillator 72.20 2.53

Price Performance

Historical Comparison
RERE
WVE

About RERE ATRenew Inc.

ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: